High factor VIIa levels do not promote tumor metastasis

• References

• 1 Klerk CP, Smorenburg SM, Otten HM. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-2135.
• 2 Kakkar AK, Levine MN, Kadziola Z. et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944-1948.
• 3 Laubli H, Stevenson JL, Varki A. et al. L-selectin facilitation of metastasis involves temporal induction of Fut7-dependent ligands at sites of tumor cell arrest. Cancer Res 2006; 66: 1536-1542.
• 4 Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins – Correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
• 5 Nierodzik ML, Plotkin A, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991; 87: 229-236.
• 6 Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10: 355-362.
• 7 Palumbo JS, Talmage KE, Massari JV. et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005; 105: 178-185.
• 8 Wang X, Wang M, Amarzguioui M. et al. Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice. Int J Cancer 2004; 112: 994-1002.
• 9 Hu L, Lee M, Campbell W. et al. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104: 2746-2751.
• 10 Nieswandt B, Hafner M, Echtenacher B. et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
• 11 Palumbo JS, Talmage KE, Massari JV. et al. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007; 110: 133-141.
• 12 Versteeg HH, Schaffner F, Kerver M. et al. Inhibition of tissue factor signalling suppresses tumor growth. Blood 2008; 111: 190-199.
• 13 Jiang X, Guo YL, Bromberg ME. Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 2006; 96: 196-201.
• 14 Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27: 1687-1693.
• 15 Spek CA. Tissue factor: from ‘just one of the coagulation factors’ to a major player in physiology. Blood Coagul Fibrinolysis 2004; 15 (Suppl. 01) S3-10.
• 16 Wiiger MT, Prydz H. The changing faces of tissue factor biology. A personal tribute to the understanding of the „extrinsic coagulation activation”. Thromb Haemost 2007; 98: 38-42.
• 17 Koizume S, Jin MS, Miyagi E. et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res 2006; 66: 9453-9460.
• 18 Tranholm M, Kristensen K. et al. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 2003; 102: 3615-3620.
• 19 Amirkhosravi A, Mousa SA, Amaya M. et al. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1: 1972-1976.
• 20 Langer F, Amirkhosravi A, Ingersoll SB. et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006; 4: 1056-1062.
• 21 Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004; 104: 3858-3864.
• 22 Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027-1035.
• 23 Kavakli K, Makris M, Zulfikar B. et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-605.
• 24 Martinowitz U, Kenet G, Segal E. et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-439.
• 25 Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. B J Obstet Gynecol 2007; 114: 8-15.
• 26 Ghorashian S, Hunt BJ. “Off-license” use of recombinant activated factor VII. Blood Rev 2004; 18: 245-259.